| SAVA (SAVA) | |||
|---|---|---|---|
| 1.32 0.03 (2.33%) | 05-22 12:35 | ||
| Open: | 1.3 | Pre. Close: | 1.29 |
| High: | 1.345 | Low: | 1.272 |
| Volume: | 134,262 | Market Cap: | 64(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 2.34 -10000000000 One year: 2.37 -10000000000 |
| Support: | Support1: 1.95 -10000000000 Support2: 1.62 -10000000000 |
| Resistance: | Resistance1: 2.00 -10000000000 Resistance2: 2.03 -10000000000 |
| Pivot: | -10000000000 |
| Moving Averages: | MA(5): MA(20): MA(100): MA(250): |
| MACD: | MACD(12,26): -10000000000.00 -10000000000 Signal(12,26,9): -10000000000.00 -10000000000 |
| %K %D: | %K(14,3): -10000000000.00 -10000000000 %D(3): -10000000000.00 -10000000000 |
| RSI: | RSI(14): -10000000000.00 -10000000000 |
| 52-Week: | High: 4.98 Low: 1.15 Change(%): |
| Average Vol(K): | 3-Month: -10000000000 10-Days: -10000000000 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SAVA ] has closed Bollinger Bands are 0% narrower than normal. |
| Company profile |
|---|
| Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. |
| Stock chart |
|---|
 |
| Stock News |
|---|
|
Wed, 27 May 2026 Antalaha, Sava, Madagascar - MSN Sat, 23 May 2026 Serbia - Rivers, Danube, Sava - Britannica Thu, 21 May 2026 Leah Sava’ Jeffries and Aryan Simhadri Tease ‘Percy Jackson and the Olympians’ Season 3 - The Nerds of Color Wed, 20 May 2026 Slovenia’s Sava posts 31 mln euro net profit in Q1 - SeeNews Mon, 11 May 2026 CGM maker Sava names new chief commercial officer - Drug Delivery Business Wed, 06 May 2026 How many employees work at Sava Healthcare? - Revelio Labs |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | |
| % Held by Insiders | |
| % Held by Institutions | |
| Shares Short (K) | |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
